Kaiser doxyPEP study is promising against STIs like syphilis

Key Points:

• A Kaiser study found that doxyPEP, an antibiotic taken within 72 hours of unprotected sex, reduces the risk of syphilis and chlamydia by up to 60%, but has lost effectiveness against gonorrhea within a year of widespread use in California.
• The study suggests doxyPEP may be contributing to antibiotic resistance in gonorrhea, though experts emphasize that doxycycline is not commonly used to treat gonorrhea due to pre-existing resistance issues.
• Despite the lack of protection against gonorrhea, public health officials continue to recommend doxyPEP, especially for high-risk groups, due to its durable benefits against syphilis and chlamydia and the serious consequences of untreated infections, particularly in women and during pregnancy.
• San Francisco has expanded doxyPEP recommendations to include cisgender women, aiming to reduce the high morbidity associated with syphilis and chlamydia in this population.
• Experts advocate for the continued, judicious use of doxyPEP as a valuable tool in STI prevention while monitoring antibiotic resistance and tailoring its application to maximize public health benefits.